Moderna Inc. diskutieren
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $225.00 to $200.00. They now have a "buy" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) was upgraded by analysts at TD Cowen from a "market perform" rating to an "outperform" rating. They now have a $180.00 price target on the stock, up previously from $150.00.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $191.00 price target on the stock, down previously from $221.00.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at TD Cowen from $175.00 to $165.00. They now have an "outperform" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at Royal Bank of Canada from $200.00 to $190.00. They now have an "outperform" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "sell" rating. They now have a $60.00 price target on the stock, down previously from $125.00.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $269.00 to $231.00. They now have a "buy" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at Royal Bank of Canada from $180.00 to $125.00. They now have an "outperform" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $142.00 price target on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $125.00 price target on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $125.00 price target on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its "reduce" rating re-affirmed by analysts at HSBC Holdings plc. They now have a $86.00 price target on the stock, up previously from $75.00.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $125.00 price target on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its "buy" rating re-affirmed by analysts at Jefferies Financial Group Inc.. They now have a $125.00 price target on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its price target raised by analysts at Oppenheimer Holdings Inc. from $142.00 to $163.00. They now have an "outperform" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its price target raised by analysts at Royal Bank of Canada from $125.00 to $135.00. They now have an "outperform" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its price target raised by analysts at UBS Group AG from $143.00 to $151.00. They now have a "buy" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Neueste Beiträge
Nils1 in Salesforce.com diskutieren